Image
Making the Call in Heart Failure Multidimensional Outcomes with SGLT2 Inhibitors

Biykem Bozkurt, MD, PhD, FHFSA, FACC, FAHA, FACP; Javed Butler, MD, MPH, MBA; Christopher P. Cannon, MD

This activity is jointly provided by Global Education Group and Integritas Communications. 

This activity is supported by an educational grant from AstraZeneca.

Target Audience

The educational design of this activity addresses the needs of cardiologists and other specialist clinicians with a focus on heart failure.

Learning Objectives

Upon completion of this activity, the participant should be better able to:

  • Evaluate patients with heart failure based on new consensus recommendations for definition, staging, and classification
  • Discuss the clinical profiles, trial designs, and recent data for SGLT-2 inhibitors in patients with HFrEF or HFpEF, including cardiovascular and renal outcomes
  • Incorporate SGLT-2 inhibitors into treatment algorithms for heart failure to reflect appropriate patient selection, safety considerations, and prescribing recommendations
  • Individualize treatment regimens for patients with heart failure with consideration of case presentation, practice guidelines, newly published evidence, and comorbidities, such as CKD

Program Overview

Heart failure medicine is dynamic, with recent approvals for use of SGLT2 inhibitors, and updated recommendations for definition, staging, and classification of heart failure. As heart failure therapies overlap into other specialties, it is more important than ever to use a patient-centered, multidisciplinary care team model. In this 90-minute Call-a-Colleague presentation, three experts will discuss the new consensus recommendations for heart failure and the evidence for using SGLT2 inhibitors in patients with different classes of heart failure as well as comorbidities. To illustrate how to individualize treatment regimens and the nuances of heart failure care, they will call in specialist colleagues for consults about practical considerations for prescribing SGLT2 inhibitors.

Faculty

Biykem Bozkurt, MD, PhD, FHFSA, FACC, FAHA, FACP
The Mary and Gordon Cain Chair and Professor of Medicine
Associate Provost of Faculty Affairs
Senior Associate Dean of Faculty Development
Director, Winters Center for Heart Failure Research
Houston, Texas

Javed Butler, MD, MPH, MBA
President, Baylor Scott and White Research Institute
Dallas, Texas
Distinguished Professor of Medicine
University of Mississippi
Jackson, Mississippi

Christopher P. Cannon, MD
Education Director, Cardiovascular Innovation 
Brigham and Women’s Hospital 
Remote faculty, Clinician-Scientist, CPC Clinical Research
Professor of Medicine, Harvard Medical School
Boston, Massachusetts

“Call-A-Colleague” Consultants

George Bakris, MD
Professor of Medicine
Section of Endocrinology, Diabetes, and Metabolism
Director, AHA Comprehensive Hypertension Center
University of Chicago Medicine
Chicago, Illinois

Alice Y. Y. Cheng, MD, FRCPC
Endocrinologist
Trillium Health Partners & Unity Health Toronto
Associate Professor, University of Toronto
Toronto, Canada

Cynthia Chauhan
Patient

Agenda

  • Preactivity Questionnaire and Faculty Introductions
  • Overview of New Heart Failure Recommendations from 2022 AHA/ACC/HFSA Guideline for the Management of  Heart Failure
  • Pathophysiology of Heart Failure - Insights Into the Mechanism of SGLT2 Inhibitors
  • Panel Discussion - Data on SGLT2 Inhibitors in Heart Failure
  • Renoprotective Outcomes from Large Clinical Trials with SGLT2 Inhibitors
  • Pulling Things Together: Comprehensive Management of Patients with Heart Failure
  • Postactivity Questionnaire and Q&A Session

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation

Global Education Group designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Global Education Group is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

This educational activity for 1.25 contact hours is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

Global Contact Information

For information about the approval of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must score at least 70% or higher on the posttest and complete the program evaluation.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Disclosures of Conflicts of Interest

Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global.  All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.  

All relevant financial relationships have been mitigated. 

The faculty have the following relevant financial relationships with ineligible companies:

Biykem Bozkurt, MD, PhD, FHFSA, FACC, FAHA, FACP: Consulting fees and Contracted research: Abbott Vascular, AstraZeneca Pharmaceuticals, Baxter, Cardurion, Liva Nova, Renovacor

Javed Butler, MD, MPH, MBA: Consulting fees: Abbott, Adrenomed AG, Amgen Inc., Applied Therapeutics, Array BioPharma, AstraZeneca Pharmaceuticals, Bayer AG, Boehringer Ingelheim, Bristol Myers Squibb Company, CVRx, G3 Pharmaceuticals Inc., Impulse Dynamics N.V., Innolife Co., Ltd., Janssen Pharmaceuticals, LivaNova PLC, Luitpold Pharmaceuticals, Inc., Medtronic plc, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Novo Nordisk A/S, Relypsa, Inc., Roche, Vifor Pharma Group. Speakers’ Bureaus: AstraZeneca Pharmaceuticals, Boehringer Ingelheim, Eli Lilly and Company, Janssen Pharmaceuticals, Novartis Pharmaceuticals Corporation.

Christopher P. Cannon, MD: Consulting fees: Aegerion/Amryt, Alnylam Pharmaceuticals, Inc., Amarin Corporation, Amgen Inc., Applied Therapeutics, Ascendia Pharmaceuticals, Boehringer Ingelheim, Bristol Myers Squibb Company, Eli Lilly and Company, Janssen Pharmaceuticals, Lexicon Pharmaceuticals, Inc., Merck & Co., Inc., Pfizer Inc., Rhoshan Pharmaceuticals, Sanofi S.A. Contracted Research: Amgen Inc., Better Therapeutics, Inc, Boehringer Ingelheim, Bristol Myers Squibb Company, Daiichi Sankyo Company, Limited, Janssen Pharmaceuticals, Merck & Co., Inc., Novo Nordisk A/S, Pfizer Inc.

George Bakris, MD (Consultant): Consulting fees: Alnylam Pharmaceuticals, Inc., AstraZeneca Pharmaceuticals, Bayer AG, DiaMedica Therapeutics, Inc., inRegen, Ionis Pharmaceuticals, Inc., Janssen Pharmaceuticals, KBP Biosciences Co., Ltd., Novo Nordisk A/S, Quantum Genomics SA. Contracted Research: Bayer AG, Novo Nordisk A/S  

Alice Y.Y. Cheng, MD, FRCPC (Consultant): Consulting Fees: Abbott, AstraZeneca Pharmaceuticals, Bayer AG, Boehringer Ingelheim, Dexcom, Inc., Eisai Co., Ltd., Eli Lilly and Company, Insulet Corporation, HLS Therapeutics, Inc., Janssen Pharmaceuticals, Novo Nordisk A/S, Sanofi S.A., Takeda Pharmaceuticals U.S.A., Inc. Honoraria: Abbott, Amgen Inc., AstraZeneca Pharmaceuticals, Bausch Health Companies Inc., Bayer AG, Boehringer Ingelheim, Dexcom, Inc., Eisai Co., Ltd., Eli Lilly and Company, GlaxoSmithKline, Insulet Corporation, HLS Therapeutics, Inc., Janssen Pharmaceuticals, Medtronic plc, Novo Nordisk A/S, Pfizer Inc., Sanofi S.A., Takeda Pharmaceuticals U.S.A., Inc. Speakers’ Bureaus: Abbott, Amgen Inc., AstraZeneca Pharmaceuticals, Bausch Health Companies Inc., Bayer AG, Boehringer Ingelheim, Dexcom, Inc., Eli Lilly and Company, GlaxoSmithKline, Insulet Corporation, HLS Therapeutics, Inc., Janssen Pharmaceuticals, Medtronic plc, Novo Nordisk A/S, Pfizer Inc., Sanofi S.A.

Cynthia Chauhan (Patient): Honoraria: Astellis

The planners and managers at Global Education Group and Integritas Communications have no relevant financial relationships to disclose. 

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Global Education Group (Global) and Integritas do not recommend the use of any agent outside of the labeled indications.  

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

 

Click "Begin Activity" to acknowledge that you have reviewed the preamble information for this activity.

Begin Activity

credit amount 1.25

credit type CME/CE

release 11/18/2022

expiration 11/18/2023

type Webcast